Corcept Therapeutics

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of medications that treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is a pioneer in the field of selective cortisol modulation and glucocorticoid receptor antagonism. Corcept's commercial portfolio includes Korlym (mifepristone), the first FDA-approved oral medication for controlling hyperglycemia secondary to hypercortisolism (Cushing's syndrome). The company is actively expanding its therapeutic reach, recently securing FDA approval for Lifyorli (relacorilant) for the treatment of platinum-resistant ovarian cancer.